OvaScience Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
59
- Latest Deal Type
-
M&A
OvaScience General Information
Description
Millendo Therapeutics Inc is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases. Its lead asset, livoletide, is an unacylated ghrelin analogue being developed for the treatment of Prader-Willi syndrome (PWS), a rare genetic disease characterized by hyperphagia, a chronic unrelenting hunger, that leads to obesity, metabolic dysfunction, reduced quality of life and early mortality. The company is also developing nevanimibe, an ACAT1 inhibitor for the treatment of two orphan adrenal diseases: classic congenital adrenal hyperplasia (CAH) and endogenous Cushing's syndrome (CS).
Contact Information
Website
www.ovascience.comCorporate Office
- 9 Fourth Avenue
- Waltham, MA 02451
- United States
Corporate Office
- 9 Fourth Avenue
- Waltham, MA 02451
- United States
OvaScience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 07-Dec-2018 | Completed | Generating Revenue | |||
| 9. 2PO | 26-May-2016 | Completed | Generating Revenue | |||
| 8. Secondary Transaction - Open Market | 08-Apr-2015 | Completed | Generating Revenue | |||
| 7. 2PO | 07-Jan-2015 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Open Market | 01-Apr-2014 | Completed | Generating Revenue | |||
| 5. PIPE | 26-Mar-2013 | Completed | Generating Revenue | |||
| 4. PIPE | 04-Jan-2013 | Completed | Generating Revenue | |||
| 3. IPO | 12-Nov-2012 | Completed | Startup | |||
| 2. Early Stage VC (Series B) | 04-Apr-2012 | $37.2M | $43.4M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 11-Oct-2011 | $6.2M | $6.2M | Completed | Startup |
OvaScience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
OvaScience Comparisons
Industry
Financing
Details
OvaScience Competitors (9)
One of OvaScience’s 9 competitors is Adienne, a Corporation company based in Lugano, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adienne | Corporation | Lugano, Switzerland | ||||
| XBiotech | Corporation | Austin, TX | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Idorsia Pharmaceuticals | Corporation | Allschwil, Switzerland | ||||
| Gilead | Formerly VC-backed | Foster City, CA |
OvaScience Signals
OvaScience Former Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Adage Capital Management | Hedge Fund | Minority | ||
| Bessemer Venture Partners | Venture Capital | Minority | ||
| Biobrit | Venture Capital | Minority | ||
| Cycad Group | Venture Capital | Minority | ||
| Deerfield Management | Venture Capital | Minority |
OvaScience Acquisitions (1)
OvaScience’s most recent deal was a Reverse Merger with Millendo Therapeutics for . The deal was made on 07-Dec-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Millendo Therapeutics | 07-Dec-2018 | Reverse Merger | Biotechnology |
OvaScience FAQs
-
When was OvaScience founded?
OvaScience was founded in 2011.
-
Where is OvaScience headquartered?
OvaScience is headquartered in Waltham, MA.
-
What is the size of OvaScience?
OvaScience has 59 total employees.
-
What industry is OvaScience in?
OvaScience’s primary industry is Biotechnology.
-
Is OvaScience a private or public company?
OvaScience is a Private company.
-
What is OvaScience’s current revenue?
The current revenue for OvaScience is .
-
How much funding has OvaScience raised over time?
OvaScience has raised $280M.
-
Who are OvaScience’s investors?
Adage Capital Management, Bessemer Venture Partners, Biobrit, Cycad Group, and Deerfield Management are 5 of 15 investors who have invested in OvaScience.
-
Who are OvaScience’s competitors?
Adienne, XBiotech, Amgen, Idorsia Pharmaceuticals, and Gilead are some of the 9 competitors of OvaScience.
-
When was OvaScience acquired?
OvaScience was acquired on 07-Dec-2018.
-
Who acquired OvaScience?
OvaScience was acquired by Millendo Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process